IFN-γ stimulated human umbilical-tissue-derived cells potently suppress NK activation and resist NK-mediated cytotoxicity in vitro

Stem Cells and Development

Volumn 22, Issue 22, 2013, Pages 3003-3014

  Noone, Cariosa ^a   Kihm, Anthony ^b   English, Karen ^a   O'Dea, Shirley ^a   Mahon, Bernard P ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b JOHNSON AND JOHNSON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GRANZYME; HLA ANTIGEN; INDOLEAMINE 2,3 DIOXYGENASE; INTERCELLULAR ADHESION MOLECULE 1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2D; PERFORIN; PROSTAGLANDIN E2; TRYPTOPHAN;

ARTICLE; CELL ACTIVATION; CELL INTERACTION; CELL KILLING; CELL THERAPY; CELL TYPE; CONTROLLED STUDY; CYTOTOXICITY; HAPLOTYPE; HUMAN; HUMAN CELL; HUMAN UMBILICAL TISSUE DERIVED CELL; IN VITRO STUDY; MESENCHYMAL STEM CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; UMBILICAL CORD; UMBILICAL VEIN ENDOTHELIAL CELL;

CELL COMMUNICATION; CELLS, CULTURED; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; DINOPROSTONE; FETAL BLOOD; GENE EXPRESSION REGULATION; GRANZYMES; HLA ANTIGENS; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERCELLULAR ADHESION MOLECULE-1; INTERFERON-GAMMA; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MESENCHYMAL STROMAL CELLS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; PERFORIN; SIGNAL TRANSDUCTION;

EID: 84888072366     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2013.0028     Document Type: Article

References (47)

1. Lund RD, S Wang, B Lu, S Girman, T Holmes, Y Sauve, DJ Messina, IR Harris, AJ Kihm, et al. (2007). Cells isolated from umbilicalcordtissuerescuephotoreceptorsandvisualfunctions in a rodentmodel of retinal disease. StemCells 25:602-611.
2. Zhang L, Y Li, M Romanko, BC Kramer, A Gosiewska, M Chopp and K Hong. (2012). Different routes of administration of human umbilical tissue-derived cells improve functional recovery in the rat after focal cerebral ischemia. Brain Res 1489:104-112.
3. Zhang L, Y Li, C Zhang, M Chopp, A Gosiewska and K Hong. (2011). Delayed administration of human umbilical tissue-derived cells improved neurological functional recovery in a rodent model of focal ischemia. Stroke 42:1437-1444.
4. Zhang L, L Yi, M Chopp, BC Kramer, M Romanko, A Gosiewska and K Hong. (2012). Intravenous administration of human umbilical tissue-derived cells improves neurological function in aged rats after embolic stroke. Cell Transplant. [Epub ahead of print]; DOI: ct0675zhang [pii] 10.3727/ 096368912X658674.
5. Cho PS, DJ Messina, EL Hirsh, N Chi, SN Goldman, DP Lo, IR Harris, SH Popma, DH Sachs and CA Huang. (2008). Immunogenicity of umbilical cord tissue derived cells. Blood 111:430-438.
6. English K, FP Barry, CP Field-Corbett and BP Mahon. (2007). IFN-gamma and TNF-alpha differentially regulate immunomodulation by murine mesenchymal stem cells. Immunol Lett 110:91-100.
7. Ryan JM, F Barry, JM Murphy and BP Mahon. (2007). Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol 149:353-363.
8. Uccelli A, L Moretta and V Pistoia. (2008). Mesenchymal stem cells in health and disease. Nat Rev Immunol 8:726-736.
9. Caplan AI. (2009). Why are MSCs therapeutic? New data: new insight. J Pathol 217:318-324.
10. Garcia-Olmo D, M Garcia-Arranz, D Herreros, I Pascual, C Peiro and JA Rodriguez-Montes. (2005). A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum 48:1416-1423.
11. Le Blanc K, I Rasmusson, B Sundberg, C Gotherstrom, M Hassan, M Uzunel and O Ringden. (2004). Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363:1439-1441.
12. Le Blanc K, F Frassoni, L Ball, F Locatelli, H Roelofs, I Lewis, E Lanino, B Sundberg, ME Bernardo, et al. (2008). Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371:1579-1586.
13. Caplan AI and JE Dennis. (2006). Mesenchymal stem cells as trophic mediators. J Cell Biochem 98:1076-1084.
14. Moretta A. (2002). Natural killer cells and dendritic cells: rendezvous in abused tissues. Nat Rev Immunol 2:957-964.
15. Biron CA. (1997). Activation and function of natural killer cell responses during viral infections. Curr Opin Immunol 9:24-34.
16. Lanier LL. (1998). NK cell receptors. Annu Rev Immunol 16:359-393.
17. Polchert D, J Sobinsky, G Douglas, M Kidd, A Moadsiri, E Reina, K Genrich, S Mehrotra, S Setty, B Smith and A Bartholomew. (2008). IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol 38:1745-1755.
18. Moretta A, C Bottino, M Vitale, D Pende, R Biassoni, MC Mingari and L Moretta. (1996). Receptors for HLA class-I molecules in human natural killer cells. Annu Rev Immunol 14:619-648.
19. Karre K, HG Ljunggren, G Piontek and R Kiessling. (1986). Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319:675-678.
20. Moretta A, C Bottino, M Vitale, D Pende, C Cantoni, MC Mingari, R Biassoni and L Moretta. (2001). Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 19:197-223.
21. Poggi A, C Prevosto, M Zancolli, P Canevali, A Musso and MR Zocchi. (2007). NKG2D and natural cytotoxicity receptors are involved in natural killer cell interaction with selfantigen presenting cells and stromal cells. Ann N Y Acad Sci 1109:47-57.
22. Boissel L, HH Tuncer, M Betancur, A Wolfberg and H Klingemann. (2008). Umbilical cord mesenchymal stem cells increase expansion of cord blood natural killer cells. Biol Blood Marrow Transplant 14:1031-1038.
23. Sotiropoulou PA, SA Perez, AD Gritzapis, CN Baxevanis and M Papamichail. (2006). Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 24:74-85.
24. Spaggiari GM, A Capobianco, H Abdelrazik, F Becchetti, MC Mingari and L Moretta. (2008). Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 111:1327-1333.
25. Gotherstrom C, A Lundqvist, IR Duprez, R Childs, L Berg and K le Blanc. (2011). Fetal and adult multipotent mesenchymal stromal cells are killed by different pathways. Cytotherapy 13:269-278.
26. Spaggiari GM, A Capobianco, S Becchetti, MC Mingari and L Moretta. (2006). Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NKcell proliferation. Blood 107:1484-1490.
27. Barry FP and JM Murphy. (2004). Mesenchymal stem cells: clinical applications and biological characterization. Int J Biochem Cell Biol 36:568-584.
28. Pittenger MF, AM Mackay, SC Beck, RK Jaiswal, R Douglas, JD Mosca, MA Moorman, DW Simonetti, S Craig and DR Marshak. (1999). Multilineage potential of adult human mesenchymal stem cells. Science 284:143-147.
29. McQueen KL, KM Dorighi, LA Guethlein, R Wong, B Sanjanwala and P Parham. (2007). Donor-recipient combinations of group A and B KIR haplotypes and HLA class I ligand affect the outcome of HLA-matched, sibling donor hematopoietic cell transplantation. Hum Immunol 68:309-323.
30. Aggarwal S and MF Pittenger. (2005). Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105:1815-1822.
31. Krampera M, L Cosmi, R Angeli, A Pasini, F Liotta, A Andreini, V Santarlasci, B Mazzinghi, G Pizzolo, et al. (2006). Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 24:386-398.
32. Duijvestein M, AC Vos, H Roelofs, ME Wildenberg, BB Wendrich, HW Verspaget, EM Kooy-Winkelaar, F Koning, JJ Zwaginga, et al. (2010). Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. Gut 59:1662-1669.
33. Hare JM, JH Traverse, TD Henry, N Dib, RK Strumpf, SP Schulman, G Gerstenblith, AN DeMaria, AE Denktas, et al. (2009). A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol 54:2277-2286.
34. Prasad VK, KG Lucas, GI Kleiner, JA Talano, D Jacobsohn, G Broadwater, R Monroy and J Kurtzberg. (2011). Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biol Blood Marrow Transplant 17:534-541.
35. Ankrum J and JM Karp. (2010). Mesenchymal stem cell therapy: Two steps forward, one step back. Trends Mol Med 16:203-209.
36. Huang XP, Z Sun, Y Miyagi, H McDonald Kinkaid, L Zhang, RD Weisel and RK Li. (2010). Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair. Circulation 122:2419-2429.
37. Poggi A, C Prevosto, AM Massaro, S Negrini, S Urbani, I Pierri, R Saccardi, M Gobbi and MR Zocchi. (2005). Interaction between human NK cells and bone marrow stromal cells induces NK cell triggering: role of NKp30 and NKG2D receptors. J Immunol 175:6352-6360.
38. Giuliani M, N Oudrhiri, ZM Noman, A Vernochet, S Chouaib, B Azzarone, A Durrbach and A Bennaceur-Griscelli. (2011). Human mesenchymal stem cells derived from induced pluripotent stem cells downregulate NK cell cytolytic machinery. Blood 118:3254-3262.
39. Pradier A, J Passweg, J Villard and V Kindler. (2011). Human bone marrow stromal cells and skin fibroblasts inhibit natural killer cell proliferation and cytotoxic activity. Cell Transplant 20:681-691.
40. Crop MJ, SS Korevaar, R de Kuiper, JN Ijzermans, NM van Besouw, CC Baan, W Weimar and MJ Hoogduijn. (2011). Human mesenchymal stem cells are susceptible to lysis by CD8 + T-cells and NK cells. Cell Transplant 20:1547-1559.
41. Askari AT, S Unzek, ZB Popovic, CK Goldman, F Forudi, M Kiedrowski, A Rovner, SG Ellis, JD Thomas, et al. (2003). Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet 362:697-703.
42. English K, JM Ryan, L Tobin, MJ Murphy, FP Barry and BP Mahon. (2009). Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4 + CD25(High) forkhead box P3 + regulatory T cells. Clin Exp Immunol 156:149-160.
43. Kavanagh H and BP Mahon. (2011). Allogeneic mesenchymal stem cells prevent allergic airway inflammation by inducing murine regulatory T cells. Allergy 66:523-531.
44. Tobin LM, M Healy, K English and BP Mahon. (2013). Human Mesenchymal Stem Cells suppress donor CD4+ T cell proliferation and reduce pathology in a humanised mouse model of acute Graft versus Host Disease. Clin Exp Immunol 172:333-348.
45. Opitz CA, UM Litzenburger, C Lutz, TV Lanz, I Tritschler, A Koppel, E Tolosa, M Hoberg, J Anderl, et al. (2009). Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3- dioxygenase-1 via interferon-beta and protein kinase R. Stem Cells 27:909-919.
46. Popp FC, E Eggenhofer, P Renner, P Slowik, SA Lang, H Kaspar, EK Geissler, P Piso, HJ Schlitt and MH Dahlke. (2008). Mesenchymal stem cells can induce long-term acceptance of solid organ allografts in synergy with low-dose mycophenolate. Transpl Immunol 20:55-60.
47. Arminan A, C Gandia, JM Garcia-Verdugo, E Lledo, C Trigueros, A Ruiz-Sauri, MD Minana, P Solves, R Paya, JA Montero and P Sepulveda. (2010). Mesenchymal stem cells provide better results than hematopoietic precursors for the treatment of myocardial infarction. J Am Coll Cardiol 55:2244-2253.